Articles tagged with Lung Cancer
A new essay published in Annals of Internal Medicine argues that physicians often have to make difficult decisions when faced with extreme political pressures. The author shares a personal story about caring for a pregnant woman who was forced to carry a baby without a brain, highlighting the need for compassion over 'choice' in patien...
The combination immunotherapy of nivolumab and ipilimumab met the primary endpoint of the NEOSTAR trial with a 33% overall major pathologic response rate in early-stage lung cancer patients. The treatment was also shown to be effective in reducing tumor viability, with six out of 21 patients achieving a complete pathological response.
The NRG-LU001 trial showed that metformin was well-tolerated by patients with locally advanced non-small cell lung cancer, but did not improve progression-free survival or overall survival rates. The study found better-than-expected PFS and OS rates in both treatment arms.
Researchers found that catastrophic genome rearrangements can occur as early as childhood and lead to lung cancer decades later. Gene fusions in non-smokers mostly occur early on, sometimes as early as childhood or adolescence, and are often dormant for several decades before progressing into cancer.
Researchers from Stand Up To Cancer will discuss their work on advancing immunotherapy for pediatric brain tumors, genome-wide cell-free DNA fragmentation profiling for early cancer detection, and personalized consolidation immunotherapy in localized non-small cell lung cancer. The findings highlight promising approaches to screening, ...
A new study presented at ASCO 2019 shows that brigatinib is effective in patients who have received another next-generation ALK inhibitor. The 40-50 percent response rate suggests that brigatinib may be a useful treatment option for these patients. Detailed molecular analyses will help determine the characteristics of patients sensitiv...
A virtual clinical trial using real-world data found entrectinib to be more effective than crizotinib in treating ROS1+ lung cancer. Patients on entrectinib stayed on treatment longer and had a 44% increased chance of cancer recurrence compared to those on crizotinib.
A new study from the University of British Columbia found that steroid inhalers can lower lung cancer risk in COPD patients. The research, published in European Respiratory Journal, analyzed data from 39,676 adults with COPD and found a 25-30% reduction in lung cancer risk among those using steroids.
Smokers of unfiltered cigarettes face a significantly higher risk of dying from lung cancer and all causes than those who smoke filtered cigarettes. Researchers found that light or ultralight cigarettes do not offer any lung cancer death reduction benefits, but smokers may be less likely to quit.
Research at ATS 2019 reveals that smokers with severe lung function limitation are more likely to die from respiratory causes. In contrast, smokers with mild impairment face a higher risk of heart disease and lung cancer.
A new AI system has been developed that can detect lung cancer with high accuracy, potentially leading to earlier treatment. The system uses deep learning to analyze low-dose chest computed tomography (LDCT) scans and performs better than human radiologists in detecting malignant nodules.
Scientists have identified a promising compound, PHT-7.3, that shrinks KRAS-driven tumors in mice by targeting the protein's partner, Cnksr1. The study provides a potential treatment for KRAS-positive cancers, which currently have no effective therapy.
A large Chinese study found that type 2 diabetes is associated with an elevated risk of 11 types of cancer in men and 13 types of cancer in women. The study, which examined data from over 410,000 adults, revealed significant increases in cancer risk for both men and women with diabetes.
New trials suggest whole body MRI can diagnose cancer stage more quickly and accurately than standard imaging for colorectal and non-small cell lung cancers. This reduces treatment decision time from an average of 13 days to 8 days, while costs are lowered by nearly a quarter in some cases.
A large study found that adults with high fitness levels had a lower risk of developing lung and colorectal cancer, as well as improved survival rates after diagnosis. Fitness testing is common among adults and may provide valuable information about cancer risk and prognosis.
A new surgical technique using ultrasonic energy to seal pulmonary artery branches has been shown to reduce post-operative bleeding, complications, and pain in patients with lung cancer. The study's results have the potential to make this less invasive procedure more widely available, leading to faster recovery times for thousands of C...
Stand Up To Cancer has awarded five research teams a total of $1.25 million to explore cross-cutting questions in cancer treatment through innovative collaboration. The grant program aims to bring together outstanding researchers from different teams to make use of the extraordinary talent across the SU2C community.
A recent study published in Cancer Epidemiology, Biomarkers & Prevention found that the prevalence of physician-patient discussions about lung cancer screening is very low and declining. In 2017, only 4.3% of the general population discussed lung cancer screening with their doctor, compared to 8.7% among current smokers in 2012.
Lung cancer in non-smokers is under-recognized, with an estimated 6,000 deaths per year in the UK. The risk factors include second-hand smoke, occupational carcinogen exposure, and outdoor pollution.
Researchers have engineered molecules that restrict access to heme, an oxygen-binding molecule, to slow the growth of lung cancer tumors in mice. By starving cancer cells of this essential molecule, the new approach may provide a potential new path forward in treating non-small cell lung cancer.
Researchers identified four genomic subtypes in smokers with precancerous lesions, where immune response is impaired. The study suggests that a therapeutic could reactivate the immune system to intercept lung cancer.
A deep-learning model developed using serial image scans of tumors from patients with non-small cell lung cancer (NSCLC) predicted treatment response and survival outcomes better than standard clinical parameters. The model's performance improved with the addition of each follow-up scan, predicting two-year survival with an accuracy of...
A short video describing lung cancer screening benefits and risks, combined with an informational brochure, increased patients' knowledge and reduced conflicted feelings about the scan. Participants who watched the video as well as read the booklet were more certain of their decision to undergo the scan.
A new American Cancer Society study highlights the need to better identify patients with metastatic cancer who may not benefit from aggressive treatment. The study found wide variations in treatment patterns among patients who died within a month of diagnosis.
New studies provide insights into the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer. Real-life studies suggest that elderly patients may have shorter overall survival but similar toxicity rates compared to younger patients.
A study of nearly 19,000 Asian patients reveals variations in lung cancer treatment, with Chinese, Indian, and Korean patients more likely to receive surgery and chemotherapy. Women were also more likely to receive these treatments than men.
Researchers map the landscape of myeloid cells in lung cancer tumors using single-cell sequencing, revealing 25 distinct subpopulations with consistent gene expression signatures across patients. The findings provide a powerful starting point to better understand their functions and clinical applications.
A study found that capsaicin, a compound in chili peppers, inhibits invasion and metastasis of lung cancer cells, slowing disease progression. The researchers also identified the protein Src as a key player in suppressing lung cancer metastasis.
Cancer research highlights canine sniffing detection, spicy compound slowing lung cancer progression. Neurodegenerative diseases examined via gum bacteria link to Alzheimer's and Parkinson's. New therapies target diabetes complications and liver failure.
Researchers found tarloxotinib effective against various cancer types, including ovarian and breast cancers with NRG1 gene fusions. The drug targets low-oxygen conditions, making it potentially more tolerable than existing therapies.
Adding savolitinib to osimertinib yields clinical responses in patients with EGFR-mutant non-small cell lung cancer and MET-driven acquired resistance. The combination therapy demonstrates efficacy in a patient population for whom chemotherapy is the current primary treatment option.
A study of over 1 million participants from China, Japan, South Korea, Singapore, Taiwan, and India found that smoking was associated with 144,366 deaths during a 12-year follow-up period. Tobacco use accounted for 56.6% of lung cancer deaths and 21.1% of total deaths among men born in the 1920s.
Research highlights the development of next-generation CAR T-cells and immune profiling to overcome tumor resistance. SU2C presents work on cancer interception, convergence, and clinical trials for pancreatic, pediatric, brain, colorectal, lung, ovarian, and breast cancers.
Researchers have developed a mini-protein MYC inhibitor that effectively treats non-small cell lung cancer, exhibiting minimal side effects. The therapy works by targeting the MYC oncogene, leading to reduced tumor growth and improved patient outcomes.
Francoise Mornex, a renowned French oncologist, has been awarded the prestigious Heine H. Hansen Award for her groundbreaking contributions to the treatment of lung cancer. Her research focuses on combined chemoradiation strategies, multimodality treatment, and innovative radiotherapy techniques.
Researchers have developed a new method to detect small fragments of cancerous genetic material in blood samples from lung cancer patients. The method, called liquid biopsy, uses ultra-deep next-generation sequencing and machine learning to identify genetic variants driving the cancer or making it resistant to treatment.
Researchers found that ZEB1 forces KRAS-driven lung cancer cells to switch from stable to mobile, resistant mesenchymal cells, making them less responsive to MEK inhibitors. A combination of an HDAC inhibitor and a MEK inhibitor reversed this transition and restored vulnerability to targeted therapy.
A VA study examined the use of video-assisted thoracoscopic lung resection in patients with known or suspected lung cancer from 2002 to 2015. The proportion of this minimally invasive procedure increased significantly over time, but its adoption varied by VA region.
Researchers at the University of Pittsburgh and UPMC Hillman Cancer Center have developed an AI model that can accurately identify benign nodules in low-dose CT scans, reducing false positives by up to 30%. This means patients with benign nodules won't need additional testing or biopsies, streamlining their care.
Researchers at University of Tsukuba uncover how stratifin causes lung adenocarcinoma to emerge, identifying two drugs with other clinical uses that could be applied effectively in this disease. The study's findings raise hopes for more powerful treatment tools and value drug repositioning as a potential solution.
A team of researchers led by James DeGregori will identify lung tissue characteristics that enable cancer cell growth, aiming to predict cancer risk and develop interventions. The study aims to modulate the lung environment to reduce cancer risk, rather than targeting cancer cells alone.
A team of researchers at Dartmouth's Norris Cotton Cancer Center has developed a deep neural network to classify different types of lung adenocarcinoma on histopathology slides. The model achieved high accuracy comparable to that of pathologists, showing great potential for assisting in prognosis and treatment.
Researchers found that sarcopenia is significantly associated with poor response to cancer treatments, including PD-1 inhibitors. Increasing muscle mass prior to treatment may predict treatment effectiveness and improve long-term outcomes for patients with advanced non-small cell lung cancer.
Scientists at Kanazawa University found that AXL protein is responsible for resistance to osimertinib, a tyrosine kinase inhibitor used to treat EGFR-mutated lung cancer. Inhibiting AXL expression can prevent tumor regrowth and improve treatment outcomes.
Researchers found that lung cancer cells acquire resistance to molecular-targeted drugs by transforming epithelial characteristics into mesenchymal ones, leading to reduced miR-200c expression. Sequential treatment with an HDAC inhibitor and a next generation molecular-targeted drug overcomes this resistance, offering new potential for...
Researchers at Osaka University have found a correlation between T cell activity in lung tumors and blood, predicting the efficacy of immune system-targeting therapy. This breakthrough enables non-invasive diagnosis and personalized treatment planning for lung cancer patients.
Researchers discovered that COPD patients often confuse early signs of lung cancer with their existing condition, leading to delayed diagnosis. The study emphasizes the need for healthcare professionals to educate patients about their increased risk and be more vigilant when symptoms change.
A research team at the University of Louisville discovered that SA-4-1BBL boosts CD8+ and CD4+ T cells to target tumors for destruction. The molecule protects healthy mice from various cancer types when exposed to tumor cells, showing promise in cancer immunoprevention.
The black-white cancer mortality gap has closed considerably over the past several decades, with faster declines among black Americans. The disparities have narrowed for lung, prostate, and colorectal cancers, and have stabilized since 2010 for breast cancer.
Researchers have found evidence of pre-cancerous lung tumours in mice using a blood-based test, suggesting a potential early detection method for lung cancer. The study used mice with a mutation in the KRAS gene to model the disease and found that circulating DNA levels correlated with tumour size.
A University of Colorado study shows that low-molecular weight PAHs, commonly found in secondhand smoke and environmental exposures, can cause cancer-promoting changes in lung cells within 30 minutes.
A study of 2,766 physicians found that those receiving payments from a cancer drug's manufacturer were more likely to prescribe the drug for certain types of cancer, including kidney and lung cancer. Financial relationships between physicians and drug companies can influence prescribing practices.
Researchers from the University of Exeter have developed a new graphene biosensor that can detect molecules of common lung cancer biomarkers. The device has the potential to revolutionize existing electronic nose devices and provide an early-stage lung cancer diagnosis through a convenient and reusable breath test.
Researchers found that lung tumors exploit altered bacterial populations to create an inflammatory environment that promotes their survival. Treating mice with antibiotics or blocking immune cells significantly reduced tumor size.
A new study found that complication rates following invasive lung cancer diagnostic tests are twice as high in the community setting compared to clinical trials, with associated downstream costs of $6,320 to $56,845 on average. The researchers emphasize the need for sharing risks with patients considering lung cancer screening.
Researchers at Osaka University have identified Semaphorin 7a as a protein involved in treatment resistance in lung cancer cells with common EGFR mutations. High levels of Semaphorin 7a inhibit apoptosis, making it harder for cancerous cells to be eradicated.
The US cancer death rate has declined by 27% since 1991, primarily due to reductions in smoking and advances in early detection and treatment. Despite this progress, socioeconomic inequalities have widened, with poorer counties experiencing a disproportionate burden of preventable cancers.
A new study found that patients with stage IV ALK-positive lung cancer have a median overall survival of 6.8 years, significantly higher than the 2 percent five-year survival rate for all NSCLC patients. This optimistic outlook is attributed to targeted therapies and careful surveillance.
A large registry-linkage study found a 13-fold increased risk of lung cancer in single lung transplant recipients' native lungs compared to the general population. Longtime since transplantation and prior smoking are associated with higher lung cancer risk.
The IASLC has launched a pilot project to develop an innovative technique for improving early lung cancer detection through shared computed tomography images. The project aims to create a globally-accessible environment for analyzing large collections of quality-controlled CT lung cancer images and associated biomedical data.